Navigation Links
World's Leading Manufacturer of IV Solutions Chooses Three RIVA Systems
Date:2/17/2010

WINNIPEG, Feb. 17 /PRNewswire/ - Following the successful integration of RIVA (Robotic IV Automation System) - a self-contained unit for filling IV syringes and bags - into three healthcare institutions in 2009, and the announcements of several more sales for installation in 2010, medical device company Intelligent Hospital Systems has confirmed the sale of three additional RIVA systems for cytotoxic drug preparation in 2010. This sale was to a major worldwide medical products and services company, who have also indicated an interest in purchasing several more systems once RIVA is fully integrated into their operations.

This is the third multi-unit deal that Intelligent Hospital Systems has signed in recent months and with the latest announcement about proven performance of RIVA in the field, confidence in the ability of automation in the IV admixture space is growing.

In addition to expediting the compounding process and enhancing patient safety, RIVA has notably improved work and safety conditions for hospital staff, reducing their exposure to a multitude of drug compounds - namely cytotoxic drugs. "With increasing concern over potential cytotoxic drug harm to workers, automated systems like RIVA that reduce drug exposure become an increasingly viable technology," notes Dr. Niels Erik Hansen, Chief Executive Officer of IH Systems. The RIVA system enables automated compounding of individual patient doses of cytotoxic drugs into a range of diverse container forms including syringes and bags, which is key to supporting safe and flexible therapy.

For Jane Arnot, IH Systems VP Customer Sales and Service, the success of RIVA in day-to-day healthcare practices is key in growing confidence and support from directors of pharmacies worldwide. "Part of the reason that the RIVA system has been so effective is its flexibility in supporting hospitals' and pharmacies' broad base of drug compounds. The three RIVA systems in place are running at least 12 different drug compounds on a regular basis for both patient specific and batch preparations. RIVA is quickly becoming an integrated part of these healthcare institutions' operations," states Arnot. "We are also very excited about the interest that we have seen worldwide in the use of RIVA for both cytotoxic drug preparation as well as non-cytotoxic drug preparation. This speaks to the confidence that our customers have that RIVA will address the unique concerns and challenges in both of these diverse environments," concludes Arnot.

RIVA (Robotic IV Automation System) - a self-contained unit for filling IV syringes and bags - is the first product developed by Winnipeg-based medical device company Intelligent Hospital Systems. For more information, please visit www.rivasystem.com.

SOURCE Intelligent Hospital Systems Ltd.


'/>"/>
SOURCE Intelligent Hospital Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Life Ionizers Drums to a New Beat with Julian Pavone, the Worlds Youngest Drummer and Inventor
2. Paging All Science and Medical Mavens: Get To Philadelphia Stat for Body Worlds and Beyond
3. BODY WORLDS Anatomical Exhibitions of Donor Bodies Receives 28 Millionth Visitor.
4. Variants of umami taste receptor contribute to our individualized flavor worlds
5. Scienceroll.com on the Medical Implications of Virtual Worlds
6. Gunther Von Hagens BODY WORLDS and KORPERWELTEN - Not Affiliated With Paris Copycat Display
7. BODY WORLDS Exhibition Uses Lung Specimens to Launch Anti-Smoking Campaign at the San Diego Natural History Museum
8. HHS AIDS.gov to Use Blogs, Virtual Worlds, and Social Networks to Deliver HIV Information for World AIDS Day 2008
9. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
10. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
11. California Science Center Welcomes 1-Millionth BODY WORLDS Visitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one of the ... 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs ... across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from around the ... - 23 in Beaver Creek, CO. It was announced today by Cindy Lovelace, executive ... Beaver Creek, hosting over 60 faculty members and addressing unmet needs of the NET ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... last long after their final treatments. Physician researchers at The Marcus Institute ... a mind-body therapy, for efficacy in reducing symptoms of traumatic stress in cancer ...
(Date:2/16/2017)... ... February 16, 2017 , ... Doctors on Liens is proud ... their network through his work at BKP Chiropractic in Lancaster . ... degree from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to open ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 Cryoablation, Electrical, ... The global ablation technologies market is expected to grow ... from 2022-2027. The market is expected to grow at a CAGR ... $3.3bn in 2016, and $9.05bn in 2026. ... How this report will benefit you ...
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 17, 2017 Theravance Biopharma, Inc. (NASDAQ: ... "Company") today announced the presentation of positive clinical ... administered pan-Janus kinase (JAK) inhibitor designed to be ... of the European Crohn,s and Colitis Organization (ECCO). ... data from its completed Phase 1 study of ...
Breaking Medicine Technology: